journal article·2021-10Open access

Macrophage‐Disguised Manganese Dioxide Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Modulating Inflammatory Microenvironment in Acute Ischemic Stroke

Chao Li, Zhenhao Zhao, Yifan Luo, Tingting Ning, Peixin Liu, Qinjun Chen, Yongchao Chu, Qin Guo, Yiwen Zhang, Wenxi Zhou, Hongyi Chen, Zheng Zhou, Yu Wang, Boyu Su, Haoyu You, Tongyu Zhang, Xuwen Li, Haolin Song, Chufeng Li, Tao Sun, Chen Jiang

Advanced Science· Volume 8· Issue 20

Abstract

Abstract Reperfusion injury is still a major challenge that impedes neuronal survival in ischemic stroke. However, the current clinical treatments are remained on single pathological process, which are due to lack of comprehensive neuroprotective effects. Herein, a macrophage‐disguised honeycomb manganese dioxide (MnO2) nanosphere loaded with fingolimod (FTY) is developed to salvage the ischemic penumbra. In particular, the biomimetic nanoparticles can accumulate actively in the damaged brain via macrophage‐membrane protein‐mediated recognition with cell adhesion molecules that are overexpressed on the damaged vascular endothelium. MnO2 nanosphere can consume excess hydrogen peroxide (H2O2) and convert it into desiderated oxygen (O2), and can be decomposed in acidic lysosome for cargo release, so as to reduce oxidative stress and promote the transition of M1 microglia to M2 type, eventually reversing the proinflammatory microenvironment and reinforcing the survival of damaged neuron. This biomimetic nanomedicine raises new strategy for multitargeted combined treatment of ischemic stroke.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neuroinflammation and Neurodegeneration Mechanisms · Nanoplatforms for cancer theranostics · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Smart Drug Delivery Ministry of Education State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science Institutes of Brain Science Department of Pharmaceutics School of Pharmacy Fudan University Shanghai 201203 China

Funding

National Natural Science Foundation of China · Program of Shanghai Academic Research Leader

References (49)

Show source-provided references
1. 10.1001/jama.2015.305810.1001/jama.2015.3058 ↗
2. 10.1136/bmj.l698310.1136/bmj.l6983 ↗
3. 10.1016/S0140-6736(16)30962-X10.1016/S0140-6736(16)30962-X ↗
4. 10.1177/0271678X1879816210.1177/0271678X18798162 ↗
5. 10.1161/STROKEAHA.115.01072110.1161/STROKEAHA.115.010721 ↗
6. 10.1161/STROKEAHA.118.02163110.1161/STROKEAHA.118.021631 ↗
7. 10.1038/jcbfm.2012.13910.1038/jcbfm.2012.139 ↗
8. 10.1177/0271678X1560672310.1177/0271678X15606723 ↗
9. 10.1038/nm.239910.1038/nm.2399 ↗
10. 10.1111/j.1747-4949.2012.00839.x10.1111/j.1747-4949.2012.00839.x ↗
11. 10.1097/00004647-200101000-0000210.1097/00004647-200101000-00002 ↗
12. 10.1111/j.1747-4949.2009.00387.x10.1111/j.1747-4949.2009.00387.x ↗
13. 10.3389/fnmol.2020.0002810.3389/fnmol.2020.00028 ↗
14. 10.1159/00006931810.1159/000069318 ↗
15. 10.3389/fneur.2019.0088910.3389/fneur.2019.00889 ↗
16. 10.1161/STROKEAHA.106.46729010.1161/STROKEAHA.106.467290 ↗
17. 10.1097/00004647-199802000-0001110.1097/00004647-199802000-00011 ↗
18. 10.1038/jcbfm.2010.710.1038/jcbfm.2010.7 ↗
19. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
20. 10.1038/nrneurol.2012.9810.1038/nrneurol.2012.98 ↗
21. 10.1038/aps.2016.16210.1038/aps.2016.162 ↗
22. 10.1161/STROKEAHA.112.65965610.1161/STROKEAHA.112.659656 ↗
23. 10.1016/j.pneurobio.2016.01.00510.1016/j.pneurobio.2016.01.005 ↗
24. 10.1002/adma.20180836110.1002/adma.201808361 ↗
25. 10.1002/anie.20180230910.1002/anie.201802309 ↗
26. 10.1161/STROKEAHA.117.01850510.1161/STROKEAHA.117.018505 ↗
27. 10.1186/s12974-019-1538-910.1186/s12974-019-1538-9 ↗
28. 10.1002/adma.20180136210.1002/adma.201801362 ↗
29. 10.1016/j.nbd.2008.08.00510.1016/j.nbd.2008.08.005 ↗
30. 10.1007/s00401-018-1815-110.1007/s00401-018-1815-1 ↗
31. 10.1021/acsnano.9b0180810.1021/acsnano.9b01808 ↗
32. 10.1007/s12017-009-8074-110.1007/s12017-009-8074-1 ↗
33. 10.1152/ajpheart.00588.200410.1152/ajpheart.00588.2004 ↗
34. 10.1016/j.surneu.2005.12.02810.1016/j.surneu.2005.12.028 ↗
35. 10.1016/j.neuint.2006.02.01110.1016/j.neuint.2006.02.011 ↗
36. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
37. 10.1021/acs.nanolett.8b0343910.1021/acs.nanolett.8b03439 ↗
38. 10.1021/acs.nanolett.7b0526310.1021/acs.nanolett.7b05263 ↗
39. 10.1161/STROKEAHA.108.53450310.1161/STROKEAHA.108.534503 ↗
40. 10.1021/jp076113n10.1021/jp076113n ↗
41. 10.2138/am.2006.192510.2138/am.2006.1925 ↗
42. 10.1039/C4CC08172B10.1039/C4CC08172B ↗
43. 10.1089/neu.2000.17.87110.1089/neu.2000.17.871 ↗
44. 10.1021/nn405773r10.1021/nn405773r ↗
45. 10.1002/adfm.20160067610.1002/adfm.201600676 ↗
46. 10.1002/ana.2242610.1002/ana.22426 ↗
47. Joni S. S. · Int. J. Physiol. Pathophysiol. Pharmacol. · 2020 · 12 · 88
48. 10.1161/01.STR.20.1.8410.1161/01.STR.20.1.84 ↗
49. 10.1124/dmd.105.00900110.1124/dmd.105.009001 ↗